- Home
- SAFT vs JANX Comparison
SAFT vs JANX Comparison
Compare SAFT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAFT | JANX |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 847.1M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SAFT | JANX |
|---|---|---|
| Price | $70.54 | $14.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 60.5K | ★ 877.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ 40.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,263,732,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $67.04 | $12.12 |
| 52 Week High | $82.09 | $35.34 |
Technical Indicators
Market Signals| Indicator | SAFT | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 52.20 |
| Support Level | $68.01 | $13.15 |
| Resistance Level | $70.49 | $15.49 |
| Average True Range (ATR) | 1.55 | 0.52 |
| MACD | -0.11 | 0.05 |
| Stochastic Oscillator | 25.84 | 80.14 |
Price Performance
Historical ComparisonAbout SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. The company operates in the business segment of Property and casualty insurance operations.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.